Skip to content
HowShorted

AERIE PHARMACEUTICALS INC short interest in 2020

In 2020, AERIE PHARMACEUTICALS INC's disclosed short interest ran from 27.78% of shares outstanding on 15 Jan 2020 to 12.50% on 31 Dec 2020, a change of -15.28 percentage points. The year's high was 27.78% on 15 Jan 2020 and its low 12.01% on 30 Nov 2020, averaging 19.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.98 days on 14 Feb 2020. Full history: AERIE PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for AERIE PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
27.78% (15 Jan 2020)
End of year
12.50% (31 Dec 2020)
Change
-15.28 pp
High
27.78% (15 Jan 2020)
Low
12.01% (30 Nov 2020)
Average
19.39%
Highest days to cover
24.98 (14 Feb 2020)
SEC filings marked
9

Every report in 2020

AERIE PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202027.78%17.97
31 Jan 202026.28%15.25
14 Feb 202026.93%24.98
28 Feb 202026.66%8.34results (8-K), 10-K filed
13 Mar 202024.93%12.77
31 Mar 202019.91%8.91
15 Apr 202020.93%10.74results (8-K)
30 Apr 202021.50%14.43
15 May 202021.11%10.50results (8-K), 10-Q filed
29 May 202021.23%10.43
15 Jun 202019.84%8.94
30 Jun 202019.36%14.76
15 Jul 202017.33%12.03
31 Jul 202019.78%17.82
14 Aug 202017.18%9.53results (8-K), 10-Q filed
31 Aug 202017.98%13.73
15 Sep 202017.73%12.12
30 Sep 202018.83%16.28
15 Oct 202016.69%16.19
30 Oct 202013.75%6.07
13 Nov 202013.18%8.08results (8-K), 10-Q filed
30 Nov 202012.01%11.78
15 Dec 202012.05%13.81
31 Dec 202012.50%11.80

See also: AERIE PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.